A NOVEL APPROACH TO

AIRWAY DISEASES

Find out more about our unique therapeutic strategy

Our non-antibiotic macrolide platform addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases.

Ā 

Tackling one of the world's most prevalent diseases

Chronic obstructive pulmonary disease (COPD) afflicts more than a quarter of a billion people globally, leading to more than 3 million deaths every year.

The unmet need for disease-modifying therapies for COPD

There are no clinical trials showing that any existing medications for COPD modify the long-term decline in lung function that characterizes COPD.

A new paradigm of epithelial barrier insufficiency

Find out more about our unique approach targeting epithelial barrier insufficiency as a key driver of inflammation in chronic respiratory diseases.

LATEST NEWS

CONTACT US

Ā 

CONTACT DETAILS

Eiưistorg 13

170 Seltjarnarnes

Iceland

[+44] 208 133 8664

SEND US A MESSAGE

Ā© 2020 by EpiEndo Pharmaceuticals     |     Legal     |     Privacy